$ cat ./records/gates-foundation-co-sponsors-who-defeating-meningitis-by-2030-roa-2020.txt
Gates Foundation Co-Sponsors WHO Defeating Meningitis by 2030 Roadmap Targeting 50% Case Reduction
[RECORD.TXT] · cat --full
The Gates Foundation co-sponsored the WHO 'Defeating Meningitis by 2030' roadmap, approved by the 73rd World Health Assembly in November 2020. The $1.5 billion plan targets elimination of bacterial meningitis epidemics, a 50 percent reduction in vaccine-preventable cases and a 70 percent reduction in deaths by 2030. Full implementation could prevent nearly 3 million cases and 900,000 deaths. The Foundation's decades of investment in MenAfriVac, MenAfriNet surveillance, and PATH meningococcal vaccine development underpins the roadmap's Africa implementation strategy.
Source: https://www.who.int/initiatives/defeating-meningitis-by-2030
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Commits $1.6 Billion to Gavi 2021–2025 Strategy at Global Vaccine Summit
Next →
Gates Foundation Backs Novel Oral Polio Vaccine Type 2 (nOPV2) for Safer Polio Eradication
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.